Alzheimer's - ADDF/Belfer ApoE Therapeutics Innovation Programme 2015 ($ 1,000,000)

The Alzheimer’s Drug Discovery Foundation (ADDF) and the Robert and Renée Belfer Family Foundation invite applications for the ADDF/Belfer ApoE Therapeutics Innovation Programme. The upcoming deadline for submitting a full proposal is September 22, 2015. The LoI is due two weeks before the proposal deadline. The programme has been established to accelerate the development of novel therapeutics specifically designed to target apoE pathological mechanisms. ADDF will provide 1 or 2 years funding for up to $ 300,000 per application for pre-clinical programs, and up to $1,000,000 per application for clinical trials of novel agents such as phase 1b or 2a studies employing biomarkers as outcome measures.

ADDF funds drug discovery research programmes from investigators in academia and biotechnology companies. In addition, ADDF initiates, sponsors, and co-sponsors conferences to stimulate new ideas and approaches in areas of interest to the Foundation, bringing together physicians, scientists, and policy makers worldwide.